| Name | dBRD9 |
| Description | dBRD9 is a PROTAC. dBRD9 is a double-acting molecule, partially containing Bromodomain-containing protein 9 (BRD9), ligand that recruits the cereblon E3 ubiquitin ligase. Ligand that recruits the cereblon E3 ubiquitin ligase. dBRD9 can inhibit the degradation of BRD9 in MOLM-13 cells, and the IC50 is 104 nM. |
| In vitro | dBRD9 has prompt rapid BRD9 degradation over a broad range of concentrations. The degraded BRD9 showed significantly enhanced efficacy(10-to-100-fold). These findings reveal the tractability of non-BET bromodomain-containing proteins to chemical degradation and highlight lead compound dBRD9 as a tool for the study of BRD9[1]. |
| In vivo | The final concentration of dBRD9 of 0.3 nM was mixed in silk fibroin hydrogel and injected into mice. It was found that BRD9 degradant alleviated ZOL-related ONJ. The ONJ-dBRD9 group is filled with well-organized newly formed trabecular bone, with 80% reduced incidence rate of osteonecrosis and periosteal reaction compared with the ONJ-control group[1]. |
| Storage | Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 10 mg/mL (12.76 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
DMSO : 150 mg/mL (191.37 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (12.76 mM), Solution.
|
| Keywords | PROTAC | dBRD9 |
| Inhibitors Related | ABBV-744 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | J-147 | 5-Ph-IAA | Bavdegalutamide | Curcumin | Naphthol AS-E | Vepdegestrant | Revumenib | JQ-1 (carboxylic acid) | Bisdemethoxycurcumin |
| Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | PPI Inhibitor Library | Bioactive Compounds Library Max |
United States
